secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2026-03-25T23:59:59+00:00
Accession:  0001193125-26-122785
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck to acquire Terns for $53.00/share ($6.7B equity value); adds CML candidate TERN-701
--------------------------------------------------------------------------------

- Merck subsidiary will pay $53.00 per share in cash, representing ~$6.7B equity value; ~$5.7B net of acquired cash.
- Premium of 31% to 60-day and 42% to 90-day VWAP as of March 24, 2026.
- Terns’ lead candidate TERN-701 is an investigational allosteric BCR::ABL1 inhibitor in Phase 1/2 for CML; FDA Orphan Drug Designation granted March 2024.
- Transaction subject to HSR waiting period, tender of >50% of Terns shares, and other customary conditions; expected to close Q2 2026.
- Merck expects ~$5.8B charge (~$2.35/share) in Q2 and full year 2026 GAAP and non-GAAP results related to the acquisition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000119312526122785/0001193125-26-122785-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000119312526122785/d86253d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-122785

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer